Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diquafosol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 known ✓ | P41231 | 12/20 | 1.00 |
| ▸ | P2RY4 known ✓ | P51582 | 7/20 | 1.00 |
| ▸ | P2RY6 known ✓ | Q15077 | 6/20 | 1.00 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diquafosol SCHEMBL17898445 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL22889034 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL21415941 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL14765538 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL24414702 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL22336797 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL24414701 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL20642231 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL21213636 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL22198897 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145529-A1 | SILVER SALT-CONTAINING OPHTHALMIC AQUEOUS COMPOSITION FILLED IN RESIN CONTAINER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210128601-A1 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| US-10729712-B2 | Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-08-04 | — | — | US | disclosed |
| US-10632139-B2 | Ophthalmic solution comprising diquafosol | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-10278985-B2 | Aqueous ophthalmic solution | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2019-05-07 | — | — | US | disclosed |
| US-20180147230-A1 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2018-05-31 | — | — | US | disclosed |
| US-20170348344-A1 | AQUEOUS OPHTHALMIC SOLUTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | P2RY2 8/4885P2RY4 13/4885P2RY6 19/4885 |
| US-10632139-B2 | Ophthalmic solution comprising diquafosol | FANCF, UACA, O60361 | P2RY2 361/4885P2RY4 456/4885P2RY6 172/4885 |
| US-20210128601-A1 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS | DSC1, DERL1, FUCA2 | P2RY2 685/4885P2RY4 1002/4885P2RY6 357/4885 |
| US-20180147230-A1 | THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS | DSC1, DERL1, FUCA2 | P2RY2 685/4885P2RY4 1002/4885P2RY6 357/4885 |
| US-10729712-B2 | Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens | DSC1, DERL1, FUCA2 | P2RY2 685/4885P2RY4 1002/4885P2RY6 357/4885 |
| US-20170348344-A1 | AQUEOUS OPHTHALMIC SOLUTION | PDE6H, AQP1, PDE6D | P2RY2 791/4885P2RY4 1118/4885P2RY6 437/4885 |
| US-10278985-B2 | Aqueous ophthalmic solution | PDE6H, AQP1, PDE6D | P2RY2 791/4885P2RY4 1118/4885P2RY6 437/4885 |
| US-20230145529-A1 | SILVER SALT-CONTAINING OPHTHALMIC AQUEOUS COMPOSITION FILLED IN RESIN CONTAINER | REV1, PRPF6, RTRAF | P2RY2 616/4885P2RY4 464/4885P2RY6 80/4885 |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | P2RY2 6/4885P2RY4 13/4885P2RY6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.